Development of an Innovative Bispecific Engager Simultaneously Binding Pd-L1 and Cd28 to Reverse Immunosuppressive Tumor Microenvironment for Enhancing Anti-Cancer Efficacy of T Cell-Based Therapies

Project: A - Government Institutionb - National Science and Technology Council

Project Details

Effective start/end date8/1/197/31/20


  • anti-PD-L1/anti-CD28 bi-functional protein drug
  • PD-1/anti-CD28 bi-functional protein drug
  • T cell therapy
  • solid tumor treatment
  • reverse tumor microenvironment
  • blocking PD-L1/PD-1inhibiotry signal
  • activating CD28 signal